understanding of risk. Active surveillance for ICD and knowledge of local epidemiology are critical to minimizing the deleterious effects of this secondary infection.

Note

Potential conflicts of interest. P. L. W. reports personal fees from Gilead, Pfizer, F2G, and MSD and meeting sponsorship from Dynaminke, Bruker, and Launch outside the submitted work. R. D. reports expert opinion fees from MSD and an educational grant from Gilead Sciences outside the submitted work. M. B. reports personal fees from Gilead and meeting sponsorship from AbbVie outside the submitted work. All remaining authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

P. Lewis White,1 Rishi Dhillon,1 Brendan Healy,2 Matthew P. Wise,3 and Matthias Baacks1

1Public Health Wales Microbiology Cardiff, University Hospital of Wales (UHW), Cardiff, United Kingdom; 2Public Health Wales Microbiology Swansea, Singleton Hospital, Swansea, United Kingdom; and 3Intensive Care Medicine, UHW, Heath Park, Cardiff, United Kingdom

References

1. White PL, Dhillon R, Cordey A, et al. A national strategy to diagnose COVID-19-associated invasive fungal disease in the ICU [manuscript published online ahead of print]. Clin Infect Dis 2020.
2. Heard KL, Hughes S, Mughal N, Moore LSP. COVID-19 and fungal superinfection. Lancet Microbe 2020; 1:e107.
3. Mastrangelo A, Germinario BN, Ferrante M, et al: on behalf of COVID-Biod Study Group. Candidemia in COVID-19 patients: incidence and characteristics in a prospective cohort compared to historical non-COVID-19 controls [manuscript published online ahead of print]. Clin Infect Dis 2020.
4. Rodriguez JY, Le Pape P, Lopez O, Esquea K, Labrova AL, Alvarez-Moreno C. Candida auris: a latent threat to critically ill patients with COVID-19 [manuscript published online ahead of print]. Clin Infect Dis 2020.
5. Arastehfar A, Carvalho A, Hong Nguyen M, et al. COVID-19-associated candidiasis (CAC): an underestimated complication in the absence of immunological predispositions? J Fungi 2020; 6:211.
6. Harrison D, Muskett H, Harvey S, et al. Development and validation of a risk model for identification of non-neutropenic, critically ill adult patients at high risk of invasive Candida infection: the Fungal Infection Risk Evaluation (FIRe) Study. Health Technol Assess 2013; 17:1–156.
7. Morales-López SE, Parra-Giraldo CM, Ceballos-Garzón A, Martínez HP, Rodríguez GJ, Álvarez-Moreno CA, Rodríguez JY. Invasive infections with multidrug-resistant yeast Candida auris, Colombia. Emerg Infect Dis 2017; 23:162–4.
8. Escandon P, Chow NA, Caceres DH, et al. Molecular epidemiology of Candida auris in Colombia reveals a highly related, countrywide colonization with regional patterns in amphotericin B resistance. Clin Infect Dis 2019; 68:15–21.

Correspondence: Dr P. Lewis White, Mycology Reference Laboratory, Public Health Wales, Microbiology Cardiff, UHW, Heath Park, Cardiff, UK. GF14 4WX (lewis.white@wales.nhs.uk)

Clinical Infectious Diseases® 2021;73(9):e2839–41 © The Author(s). 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. DOI: 10.1093/cid/ciaa1597

Reinfection of Severe Acute Respiratory Coronavirus 2 in an Immunocompromised Patient: A Case Report

To the Editor—Knowing the frequency and natural course of reinfections is important for control of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Recently, To et al published a report of a 33-year-old Hong Kong resident with a SARS-CoV-2 re-infection, confirmed by whole-genome sequencing [1]. Here, we report a case of a reinfection in an 89-year-old Dutch woman suffering from Waldenström macroglobulinemia, treated with B-cell-depleting therapy. She presented to the emergency department with fever and severe cough and a lymphocyte count of 0.4 × 10^3 cells/L. An in-house SARS-CoV-2 reverse-transcription quantitative polymerase chain reaction (RT-qPCR) assay (E-gen) [2] on a nasopharyngeal swab was positive (cycle quantification value [Cq] = 26.2). She was discharged after 5 days; other than some persisting fatigue, her symptoms subsided completely.

Two days after a new chemotherapy treatment, 59 days after the start of the first coronavirus disease 2019 episode, the patient developed fever, cough, and dyspnea. At admission, her oxygen saturation was 90% with a respiratory rate of 40 breaths per minute. The SARS-CoV-2 RT-qPCR assay on a nasopharyngeal swab was positive (E-gen; Cq = 25.2). At days 4 and 6, serum was tested for SARS-CoV-2 antibodies using the Wantai SARS-CoV-2 total antibody and the immunoglobulin M enzyme-linked immunosorbent assays; both were negative. At day 8, the condition of the patient deteriorated, and she died 2 weeks later.

The viral genomes of both episodes were compared using SARS-CoV-2–specific multiplex qPCR and Nanopore sequencing [3]. The 2 strains differed at 10 nucleotide positions in the ORF1a (4), ORF1b (2), Spike (2), ORF3a (1), and M (1) genes (Figure 1) and the sequences did not cluster in the phylogenetic tree (Supplementary Figure 1). Although we did not have PCR-negative samples in between episodes, with an average estimated SARS-CoV-2 mutation rate of 33 nucleotides per year (or 5–6 nucleotides per 2 months) [4], it is likely that the second episode was a reinfection rather than prolonged shedding.

In contrast to the Hong Kong resident, our patient experienced a more severe second episode. This has also been described in a 25-year-old Nebraska resident with no underlying comorbidities [5]. Our patient was immunocompromised because of Waldenström macroglobulinemia treated with B-cell-depleting therapy, resulting in a declined humoral immunity [6]. However, it was shown that B-cell-depleting therapy does not necessarily result in life-threatening disease, suggesting that the innate immune response and T-cell immunity can be sufficient to eliminate SARS-CoV-2 [7].

SARS-CoV-2 reinfections are expected to occur once antibody titers decrease and immunity wanes. Although a recent population study in Iceland has shown that antibodies to SARS-CoV-2 did not decline within 4 months after infection [8], reinfections in seasonal coronaviruses, such as human coronaviruses NL63, 229E, OC43, and HUK1, were observed as early as 6 months postinfection. Frequent reinfections were shown from 12 months postinfection [9]. The Hong Kong resident did not have measurable antibodies at the start of the second episode, which occurred 4–5 months after the first. However, the second episode

Correspondence: CID 2021;73 (1 November) • e2841
was asymptomatic, indicating sufficient immunological memory. Our patient and the Nevada patient suffered from an early reinfection within 2 months, unfortunately without serum samples in between episodes. The Nevada resident did develop a measurable antibody response after the second episode. Our patient did not have antibodies 6 days after start of the second episode, but seroconversion can take a few days longer.

**Supplementary Data**

Supplementary materials are available at Clinical Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

**Note**

Potential conflicts of interest. The authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.

**References**

1. To KK, Hung IF, Ip JD, et al. COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing. Clin Infect Dis 2020; doi:10.1093/cid/ciaa1275.
2. Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill 2020; 25:2000045.
3. Oude Munnink BB, Nieuwenhuijse DF, Stein M, et al. Dutch-Covid-19 response team. Rapid SARS-CoV-2 whole-genome sequencing and analysis for informed public health decision-making in the Netherlands. Nat Med 2020; 26:1405–10.
4. Candido DS, Claro IM, de Jesus JG, et al. Brazil-UK Centre for Arbovirus Discovery, Diagnosis, Genomics and Epidemiology (CADDE) Genomic Network. Evolution and epidemic spread of SARS-CoV-2 in Brazil. Science 2020; 369:1255–60.
5. Tillett RS, Hartley P, Kervin H, et al. Genomic evidence for a case of reinfection with SARS-CoV-2. SSRN [Preprint]. August 31, 2020. doi:10.2139/ssrn.3680955.
6. Karlsson J, Andréasson B, Kondori N, et al. Comparative study of immune status to infectious agents in elderly patients with multiple myeloma, Waldenstrom’s macroglobulinemia, and monoclonal gammopathy of undetermined significance. Clin Vaccine Immunol 2011; 18:969–77.
7. Argudín MA, Deplano A, Meghraoui A, et al. Bacteria from animals as a pool of antimicrobial resistance genes. Antibiotics 2017; 6:12.
8. Gudbjartsson DF, Norddahl GL, Melsted P, et al. Humoral immune response to SARS-CoV-2 in Iceland. N Engl J Med 2020. Available at: https://www.nejm.org/doi/full/10.1056/NEJMoa2004116.
9. Edridge AWD, Kaczorowska JM, Hoste ACR, et al. Coronavirus protective immunity is short-lasting. Nat Med 2020; doi:10.1038/s41591-020-086439.

More Evidence Is Warranted to Establish the Role of 18FDG-PET/CT in Fever of Unknown Origin (FUO) Investigations Among Children

To the Editor—We read with great interest the article by Wright et al entitled “Imaging a Fever—Redefining the Role of 18FDG-PET/CT in FUO Investigations” [1]. The paper aims at providing an overview of the clinical benefits and cost-effectiveness of 2-deoxy-2-[18F] fluoro-D-glucose positron emission tomography/computed tomography (18FDG-PET/CT) in the investigation of fever of unknown origin (FUO). We complement this article by raising a discussion about applying 18FDG-PET/CT in FUO investigations in the pediatric population, for which evidence is insufficient and relatively weak.

Evidence in adults is unsuitable to support the use of 18FDG-PET/CT in children, since the definition, etiology, and evaluation of FUO differ between children and adults. While FUO is well defined in adults, no consensus has been achieved in children. Various definitions have been applied throughout the years, and fevers lasting from 5 days to 3 weeks are acceptable to diagnose FUO in children [2, 3]. Moreover, the disease spectrum in children is highly age dependent, with 3 traditionally considered age groups: neonates or infants to 1 month of age, infants from 1 month to 3 months of age, and children from 3 months to 3 years of age [4]. Furthermore, children, especially young children, are not able to fully participate in the interaction with doctors, and hence objective information acquired from 18FDG-PET/CT might reveal more clues than that in adults. However, children are more sensitive to radiation than adults. Consequently, the benefits from 18FDG-PET/CT should be carefully re-examined in pediatric patients with FUO.

Very limited evidence is available on the role of 18FDG-PET/CT in pediatric FUO. We rescreened a literature database to include all cohort studies examining the